強
強気
強気 · 25%KYTX
$4.24
シナリオ価格
$5.390
-0.320 (-5.93%)終値時点
Loading chart…
- 高値
- 5.680
- 始値
- 5.680
- 出来高加重平均価格
- 5.48
- 出来高
- 827.75K
- 時価総額
- —
- 安値
- 5.360
- 売買代金
- 4.53M
- EV/EBITDA（TTM）
- 0.00
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
AI分析 of Kyverna Therapeutics Inc (KYTX)
売りKyverna Therapeutics Inc is not a good buy right now due to significant financial losses and negative momentum. The current price is $5.39, and the stock has a 1-year change of -30.99%. Furthermore, the RSI is at 27.395, indicating oversold conditions, but the overall trend remains negative. The company reported a net loss of $39,728,000 in Q1 2026, and the forward P/E is at 0, suggesting no earnings growth in the near term. The main risk is the ongoing investigations into corporate governance breaches, which could further impact investor confidence.
バリュエーション指標
Kyverna Therapeutics Inc（KYTX）の現在の予想PERは0.00で、5年平均は-2.51です。
Alphio AI による KYTX の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
KYTX を保有するクジラ
イベントタイムライン
ニュース
9.010-23NewsfilterMiv-cel Shows Promising Efficacy in Progressive Multiple Sclerosis
7.010-22PRnewswireInvestigation into Kyverna Therapeutics' Corporate Governance Breaches
- 7.010-22Newsfilter
Investigation into Kyverna Therapeutics' Fiduciary Duties
- 9.010-21Newsfilter
Miv-cel Achieves Breakthrough Efficacy in Stiff Person Syndrome
9.009-24stocktwitsKyverna's Miv-cel Shows Promising Results in Stiff Person Syndrome Study
KYTX のよくある質問 — Alphio AI が回答
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Kyverna Therapeutics Inc is not a good buy right now due to significant financial losses and negative momentum. The current price is $5.39, and the stock has a 1-year change of -30.99%. Furthermore, the RSI is at 27.395, indicating oversold conditions, but the overall trend remains negative. The company reported a net loss of $39,728,000 in Q1 2026, and the forward P/E is at 0, suggesting no earnings growth in the near term. The main risk is the ongoing investigations into corporate governance breaches, which could further impact investor confidence.
コミュニティ
もっと見る ↗
$KYTX Swarmer's miv-cel shows positive results in stiff person syndrome and gMG Kyverna Therapeutics announced positive one-year topline data from KYSA-8, its registrational trial of miv-cel - mivocabtagene autoleucel, KYV-101 - in patients with stiff person syndrome or SPS, and positive topline longer-term follow-up data from the Phase 2 portion of KYSA-6, its registrational trial in patients with generalized myasthenia gravis, or gMG. Data from both trials will be shared at upcoming medical meetings. The primary endpoint and all key secondary endpoints were achieved with statistical significance in KYSA-8. The topline one-year durability data further strengthen the positive results. Miv-cel continued to be well-tolerated. Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE. Kyverna intends to include the one-year data in its rolling BLA submission, on track to be completed in Q4. The full data set will be presented at MS Toronto, October 21-23, in Toronto. All 7 patients achieved clinically meaningful improvement in MG-ADL and QMG, co-primary endpoints of the ongoing Phase 3 portion. All 7 patients remained free of immunotherapies for MG. Miv-cel continued to be well-tolerated. The Phase 3 portion of the KYSA-6 trial is ongoing, with enrollment expected to be completed in mid-2027.
もっと見る本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。